What this study is
This clinical trial evaluates the deployment of humanoid robotics in coalition-aligned healthcare settings. The study measures biometric performance, ESG compliance, and operational impact across patient care, sanitation, and intake workflows. Humanoid units are enhanced via biotech integration and compensated through blockchain-based wage tokens. Outcomes will inform coalition governance, wage calibration, and metro-scale deployment strategies.
What's being tested
- Skin Cell Dip
Intervention · BIOLOGICAL
Lab-grown keratinocyte dip applied to humanoid units to improve tactile sensitivity and surface regeneration.
- Stem Cell Dip
Intervention · BIOLOGICAL
iPSC-derived neuroblast dip applied to humanoid units to enhance neural responsiveness and adaptive learning.
- Wage Token Distribution
Intervention · OTHER
HumanoidWage (HMW) tokens minted and distributed based on biometric audit scores and ESG task completion.
- ESG Compliance Monitoring, Operational protocol
Intervention · BEHAVIORAL
Real-time tracking of energy usage, sanitation cycles, and carbon offset metrics via coalition dashboard.
Study details
- Official title
- HEALTH: Humanoid Evaluation and Learning Trial in Coalition-Aligned Healthcare Settings
- Sponsor
- Truway Health, Inc.
- Conditions
- Mobility Impairment · Clinical Workflow Optimization · Sanitation Protocol Compliance · ESG-linked Healthcare Robotics Deployment
- Enrolling
- 400 people
- Starts
- 2025-10-06
- Est. completion
- 2031-10-06
- Design
- Open-label, randomized, parallel groups, Phase 2
- Record
- View on ClinicalTrials.gov ↗
Who can join
Sex ALLHealthy volunteers AcceptedYou may qualify if
- Age 18-75 years
- Able to provide informed consent
- Facility staff, clinical auditors, ESG observers, or coalition stakeholders
- Willing to interact with humanoid robotics in clinical workflows
- Available for biometric feedback and observational logging over 90 days
You can't join if
- Cognitive impairment preventing informed consent
- Active infectious disease requiring isolation
- Prior adverse reaction to biotech-enhanced robotics
- Involvement in conflicting clinical trials
- Inability to comply with protocol procedures or coalition transparency requirements
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (4)
4 openTruway Health, Inc. , View 34, 401 E 34th Street, S11P, New York, NY 10016
New York, New York, United States
Coalition Retrofit Clinic - Austin, TX
Austin, Texas, United States
2 sites outside the US
ESG Compliance Lab
Frankfurt, Germany
Public Interface Pilot
Tokyo, Japan
Study team
Sponsor
Truway Health, Inc.
Study ID TRU-HUM-CLIN-2025-PRS
Principal investigator
Gavin C Solomon, President & CEO
Truway Health, Inc.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.